Lexaria Bioscience Sets Jan 27 Shareholder Meeting; Board, Auditor Votes Loom

Ticker: LEXX · Form: DEF 14A · Filed: Dec 10, 2025

Sentiment: neutral

Topics: Proxy Statement, Annual Meeting, Corporate Governance, Director Election, Auditor Ratification, Shareholder Vote, Bioscience

Related Tickers: LEXX

TL;DR

**LEXX's upcoming shareholder meeting is a routine governance check, but watch for any dissent on director elections or auditor ratification as a signal of underlying issues.**

AI Summary

Lexaria Bioscience Corp. (LEXX) is holding its 2026 Annual Shareholder Meeting on January 27, 2026, via Event Conferencing, where shareholders will vote on the election of seven Director nominees, including CEO Richard Christopher and President & CSO John Docherty. The company also seeks ratification of MaloneBailey LLP as its independent registered public accounting firm for the fiscal year ending August 31, 2026, and approval of all lawful acts of the Directors since the last meeting. As of the December 1, 2025 record date, 22,225,846 shares of common stock were outstanding and entitled to vote. Shareholders are encouraged to vote by proxy, with instructions provided for both registered holders and those holding shares in 'street name'. A Q&A session regarding Lexaria's strategic business plan and research study programs, as outlined in the January 30, 2025 strategic letter, will follow the formal meeting, with questions to be submitted in advance to Head of Legal, Vanessa Carle.

Why It Matters

This DEF 14A filing outlines Lexaria Bioscience's upcoming annual meeting, which is crucial for investors as it determines the leadership and governance structure for the next year. The election of seven directors, including key executives Richard Christopher and John Docherty, directly impacts the company's strategic direction and operational execution. Ratifying MaloneBailey LLP as the auditor provides transparency and oversight, essential for investor confidence. For employees and customers, a stable and well-governed company ensures continuity and focus on its strategic business plan and research study programs, particularly in a competitive bioscience landscape where innovation and clear leadership are paramount.

Risk Assessment

Risk Level: low — The filing is a standard DEF 14A proxy statement, primarily detailing procedural matters for the upcoming annual meeting on January 27, 2026. It does not disclose new financial results, operational challenges, or significant strategic shifts that would inherently increase investment risk. The proposals are routine: electing directors, ratifying the auditor, and approving past director acts, indicating a low immediate risk from the content of this specific filing.

Analyst Insight

Investors should review the director nominees' backgrounds and the auditor's history to ensure alignment with their investment thesis. Submit any questions regarding Lexaria's strategic business plan or research studies to Vanessa Carle by January 25, 2026, to gain clarity on future direction.

Financial Highlights

debt To Equity: N/A
revenue: $N/A
operating Margin: N/A%
total Assets: $N/A
total Debt: $N/A
net Income: $N/A
eps: $N/A
gross Margin: N/A%
cash Position: $N/A
revenue Growth: +N/A%

Executive Compensation

Name	Title	Total Compensation
Richard Christopher	Chief Executive Officer	$N/A
John Docherty	President, CSO and Director	$N/A
Michael Shankman	Chief Financial Officer	$N/A

Key Numbers

2026 — Annual Meeting Year (The year for which the annual shareholder meeting is being held.)
January 27, 2026 — Annual Meeting Date (The scheduled date for Lexaria Bioscience Corp.'s annual shareholder meeting.)
1:00 p.m. PT — Annual Meeting Time (The scheduled start time for the annual shareholder meeting.)
December 1, 2025 — Record Date (The date shareholders must hold shares to be eligible to vote at the meeting.)
22,225,846 — Shares Outstanding (The total number of common shares issued and outstanding as of the Record Date, entitled to vote.)
7 — Director Nominees (The number of individuals proposed for election to the Board of Directors.)
August 31, 2026 — Fiscal Year End (The fiscal year for which MaloneBailey LLP is proposed to be ratified as the independent registered public accounting firm.)
33.33% — Quorum Requirement (The percentage of issued shares required to be present for a quorum at the meeting.)
December 10, 2025 — Proxy Materials Availability Date (The date proxy materials were first made available to shareholders.)
48 hours — Proxy Submission Deadline (The minimum time before the meeting that proxies must be received (excluding weekends/holidays).)

Key Players & Entities

Lexaria Bioscience Corp. (company) — Registrant and subject of the DEF 14A filing
Richard Christopher (person) — Director & CEO of Lexaria Bioscience Corp.
John Docherty (person) — Director, President & CSO of Lexaria Bioscience Corp.
Chris Bunka (person) — Director & Chairman of Lexaria Bioscience Corp.
Michael Shankman (person) — CFO of Lexaria Bioscience Corp.
Nicholas Baxter (person) — Director of Lexaria Bioscience Corp.
William Edward (Ted) McKechnie (person) — Director of Lexaria Bioscience Corp.
Albert Reese Jr. (person) — Director of Lexaria Bioscience Corp.
Bal Bhullar (person) — Director of Lexaria Bioscience Corp.
MaloneBailey LLP (company) — Auditor for Lexaria Bioscience Corp.

FAQ

When is Lexaria Bioscience Corp.'s 2026 Annual Meeting of Shareholders?

Lexaria Bioscience Corp.'s 2026 Annual Meeting of Shareholders is scheduled for Tuesday, January 27, 2026, at 1:00 p.m. PT, and will be held via Event Conferencing.

Who are the Director nominees for Lexaria Bioscience Corp. at the upcoming meeting?

The seven Director nominees for Lexaria Bioscience Corp. are Richard Christopher, John Docherty, Christopher Bunka, Nicholas Baxter, William Edward (Ted) McKechnie, Albert Reese Jr., and Bal Bhullar.

What is the record date for voting at Lexaria Bioscience Corp.'s annual meeting?

The record date for determining shareholders entitled to vote at Lexaria Bioscience Corp.'s annual meeting is the close of business on December 1, 2025.

Which accounting firm is Lexaria Bioscience Corp. proposing to ratify as its auditor?

Lexaria Bioscience Corp. is proposing to ratify MaloneBailey LLP as its independent registered public accounting firm for the fiscal year ending August 31, 2026.

How many shares of common stock were outstanding and entitled to vote as of the record date for Lexaria Bioscience Corp.?

As of the December 1, 2025 record date, 22,225,846 shares of Lexaria Bioscience Corp.'s common stock were issued and outstanding and entitled to vote.

How can Lexaria Bioscience Corp. shareholders ask questions about the proposals?

Shareholders can email questions regarding the proposals in advance of the meeting to Vanessa Carle, Head of Legal, at vcarle@lexariabioscience.com, with a maximum of two questions per proposal to be answered during the meeting.

What is the quorum requirement for Lexaria Bioscience Corp.'s annual meeting?

A quorum for Lexaria Bioscience Corp.'s annual meeting requires the holders of at least 33.33% of the issued shares entitled to vote as of the Record Date, present in person (via Event Conferencing) or by proxy.

What is the Board's recommendation on the proposals for Lexaria Bioscience Corp.?

Lexaria Bioscience Corp.'s Board recommends voting 'FOR' the election of each Director nominee and 'FOR' all proposals noted under items 2 (auditor ratification) and 3 (ratification of directors' acts).

Will there be a Q&A session after Lexaria Bioscience Corp.'s formal meeting?

Yes, a Q&A session will be held after the formal meeting to discuss Lexaria's strategic business plan and research study programs, with questions to be submitted in advance to Vanessa Carle.

What happens if a Lexaria Bioscience Corp. shareholder receives more than one proxy card?

If a Lexaria Bioscience Corp. shareholder receives more than one proxy card, it means shares are held in multiple names or accounts, and each proxy card should be voted to ensure all shares are counted.

Industry Context

Lexaria Bioscience Corp. operates in the biotechnology sector, focusing on developing and commercializing its Dehydra-Charge™ and other patented technologies for enhanced delivery of active ingredients. The industry is characterized by significant research and development investment, long product development cycles, and a complex regulatory landscape. Companies in this space often seek strategic partnerships and face competition from established pharmaceutical and biotech firms, as well as emerging players.

Regulatory Implications

As a bioscience company, Lexaria is subject to stringent regulations from bodies like the FDA and Health Canada concerning the development, testing, and marketing of its products. Compliance with these regulations is critical and can impact timelines and the commercial viability of its technologies. Any missteps in regulatory processes could lead to significant delays or outright rejection of product candidates.

What Investors Should Do

Review the proxy materials carefully to understand the proposals being voted on, particularly the election of directors and the ratification of the independent auditor.
Vote your shares by proxy or in person at the Annual Meeting on January 27, 2026, to ensure your voice is heard on important corporate matters.
Submit questions in advance for the Q&A session regarding Lexaria's strategic business plan and research programs to gain further insight into the company's direction.

Key Dates

2025-12-01: Record Date — Shareholders must hold shares as of this date to be eligible to vote at the Annual Meeting.
2025-12-10: Proxy Materials Availability Date — Indicates when shareholders were first able to access the proxy materials for the upcoming meeting.
2026-01-27: Annual Meeting Date — The date of the Annual Shareholder Meeting where key proposals will be voted upon.
2026-08-31: Fiscal Year End — The fiscal year for which the independent auditor is proposed to be ratified.

Glossary

DEF 14A: A filing with the SEC that provides detailed information about a company's annual shareholder meeting, including director nominees, executive compensation, and proposals to be voted on. (This document is the primary source of information for shareholders regarding the upcoming annual meeting and voting matters.)
Proxy: A document that authorizes another person to act on behalf of a shareholder, typically to vote shares at a shareholder meeting. (Shareholders can vote by proxy if they cannot attend the meeting in person, ensuring their vote is counted.)
Record Date: A specific date set by a company to determine which shareholders are eligible to receive dividends, vote at meetings, or exercise other shareholder rights. (Establishes the cutoff for determining who is entitled to vote at the January 27, 2026, Annual Meeting.)
Beneficial Ownership: The ultimate right to control or benefit from a security, even if the security is registered in another person's name. (Used to identify significant shareholders and management's holdings in the company.)
Independent Registered Public Accounting Firm: An external audit firm that meets specific independence requirements set by regulatory bodies, responsible for auditing the company's financial statements. (Shareholders are asked to ratify the appointment of Malone Bailey LLP, ensuring the integrity of the company's financial reporting.)

Year-Over-Year Comparison

This filing pertains to the 2026 Annual Shareholder Meeting, and direct year-over-year comparisons of financial metrics like revenue, net income, or margins are not available within this proxy statement itself, as it primarily focuses on governance and voting matters. The provided context includes the fiscal year ending August 31, 2025, for which the Annual Report on Form 10-K was filed on November 26, 2025, suggesting that a prior proxy statement would have covered the 2025 meeting.

Filing Stats: 4,856 words · 19 min read · ~16 pages · Grade level 13.3 · Accepted 2025-12-10 10:56:16

Key Financial Figures

$0.001 — h full voting rights and a par value of $0.001 per share. As of the Record Date a tota

Filing Documents

lxrp_def14a.htm (DEF 14A) — 475KB
lxrp_def14aimg20.jpg (GRAPHIC) — 183KB
lxrp_def14aimg15.jpg (GRAPHIC) — 6KB
lxrp_def14aimg16.jpg (GRAPHIC) — 1KB
lxrp_def14aimg17.jpg (GRAPHIC) — 1KB
lxrp_def14aimg18.jpg (GRAPHIC) — 1KB
lxrp_def14aimg19.jpg (GRAPHIC) — 10KB
0001640334-25-002275.txt ( ) — 1339KB
lxrp-20250831.xsd (EX-101.SCH) — 4KB
lxrp-20250831_lab.xml (EX-101.LAB) — 12KB
lxrp-20250831_cal.xml (EX-101.CAL) — 1KB
lxrp-20250831_pre.xml (EX-101.PRE) — 8KB
lxrp-20250831_def.xml (EX-101.DEF) — 2KB
lxrp_def14a_htm.xml (XML) — 92KB

Security Ownership of Certain Beneficial Owners and Management

Security Ownership of Certain Beneficial Owners and Management 6 DIRECTOR NOMINEES 7 Board Diversity 7 Business Experience 7 Executive Officers 10 Family Relationships 10 Involvement in Certain Legal Proceedings 10 Corporate Governance 11 Committees of the Board of Directors 13 AUDIT AND FINANCE COMMITTEE REPORT 14 Director Independence 15 Shareholder Communications with Our Board of Directors 15 Board Leadership Structure 15 Risk Oversight 15 Section 16(a) Beneficial Ownership Reporting Compliance 16

Executive Compensation

Executive Compensation 16 Compensation Discussion and Analysis 19 Compensation Plans 22 Other Forms of Compensation 23 Pay vs Performance 25 Compensation of Directors 26 Securities Authorized for Issuance under Equity Compensation Plans 26 Transactions with Related Persons and Related Person Transaction Policy 27 Anti-Hedging Policy 27 Employment Agreements 27 Fees Paid to Our Independent Registered Public Accounting Firm 27 i Table of Contents PROPOSALS FOR SHAREHOLDER VOTE 29 Proposal 1 Election of Directors 29 Proposal 2 Ratification of the Continued Appointment of the Independent Registered Public Accounting Firm 29 Proposal 3 Ratification and Approval of Acts of the Directors 30 INTEREST OF CERTAIN PERSONS IN MATTERS TO BE ACTED UPON 30 "HOUSEHOLDING" OF PROXY MATERIALS 30 SHAREHOLDER PROPOSALS 30 WHERE YOU CAN FIND MORE INFORMATION 31 SOLICITATION OF PROXIES 31 OTHER MATTERS 31 ii Table of Contents LEXARIA BIOSCIENCE CORP. 100 – 740 McCurdy Road Kelowna, BC, Canada V1X 2P7 Telephone: (250) 765-6424 PROXY STATEMENT ANNUAL MEETING OF SHAREHOLDERS TO BE HELD ON JANUARY 27, 2026 GENERAL INFORMATION ABOUT THE MEETING OF SHAREHOLDERS The Board of Directors of Lexaria Bioscience Corp. (" Lexaria ", " we ", " us " or " our ") is soliciting proxies for use at the Annual Meeting of Shareholders to be held via Event Conferencing by way of calling: for Toronto residents 416-764-8658 ; and for all others 1-888-886-7786 , at 1:00 p.m. (PT), on Tuesday, January 27, 2026 or at any adjournment of the Annual Meeting (the " Meeting "). This proxy statement, the attached notice of the Meeting, a proxy card and our Annual Report on Form 10-K for the year ended August 31, 2025, as filed with the Securities and Exchange Commission on November 26, 2025 are collectively referred to as the " proxy materials ". The proxy materials are first being made available to our shareholders on or about December 10

Security Ownership of Certain Beneficial Owners and Management

Security Ownership of Certain Beneficial Owners and Management The following table sets forth, as of the Record Date, certain information with respect to the beneficial ownership of our common shares by each shareholder known by us to be the beneficial owner of more than 5% of our common shares, as well as by each of our current Directors and executive officers as a group. Each person has sole voting and investment power with respect to the common shares, except as otherwise indicated. Beneficial ownership consists of a direct interest in the common shares, except as otherwise indicated. Name, Address & Position of Beneficial Owner (1)(2) Amount and Nature of Beneficial Percentage of Class (3) Directors and Executive Officers as a Group 1,958,682 (4) 8.39 % Executive Officers and Directors Individually Richard Christopher Chief Executive Officer 415,000 (5) 1.51 % John Docherty President, CSO and Director 370,285 (6) 1.64 % Christopher Bunka Chairman & Director 840,289 (7) 3.75 % Nicholas Baxter Independent Director 74,000 (8) * % Ted McKechnie Independent Director 81,191 (9) * % Albert Reese Jr. Independent Director 53,917 (10) * % Bal Bhullar Independent Director 24,000 (11) * % Michael Shankman Chief Financial Officer 100,000 (12) * % * denotes a holding of less than 1% Notes: (1) Under Rule 13d-3, a beneficial owner of a security includes any person who, directly or indirectly, through any contract, arrangement, understanding, relationship, or otherwise has or shares: (i) voting power, which includes the power to vote, or to direct the voting of shares; and (ii) investment power, which includes the power to dispose or direct the disposition of shares. Certain shares may be deemed to be beneficially owned by more than one person (if, for example, persons share the power to vote or the power to dispose of the shares). In addition, shares are deemed to be be